Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycaemic" glucose without numerically changing the incretin effect in patients with type 2 diabetes

被引：0
|
作者：
Foley, J. E. [1 ]
Becker, L. [2 ]
Koethe, L. [2 ]
Dejager, S. [3 ]
Schweizer, A. [4 ]
Nauck, M. A. [2 ]
机构：
[1] Novartis, E Hanover, NJ USA
[2] Diabet Zentrum, Bad Lauterberg Im Harz, Germany
[3] Novartis, Paris, France
[4] Novartis, Basel, Switzerland
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
917
引用
收藏
页码：S367 / S367
页数：1
相关论文
共 50 条
  • [41] Cardiovascular outcomes with the incretin-based therapies GLP-1 agonists and DPP-4 inhibitors in type 2 diabetes participants with and without heart failure
    Zheng, S. L.
    Collins, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 202 - 203
  • [42] Effect of oral administration of vitamin D on glucose tolerance and insulin secretion in type 2 diabetes mellitus
    Ayesha, I
    Raghunath, M
    Sesikeran, B
    Raghuramulu, N
    DIABETES NUTRITION & METABOLISM, 1998, 11 (05) : 261 - 265
  • [43] Assessment of insulin secretion from the oral glucose tolerance test in white patients with type 2 diabetes
    Stumvoll, M
    Mitrakou, A
    Pimenta, W
    Jenssen, T
    Yki-Järvinen, H
    Van Haeften, T
    Häring, H
    Fritsche, A
    Gerich, J
    DIABETES CARE, 2000, 23 (09) : 1440 - 1441
  • [44] Sustained 24hr elevation of active GLP-1 and GIP but reduced secretion during DPP-4 inhibition in type 2 diabetes subjects: comparison of three different DPP-4 inhibitors
    Alsalim, W.
    Goransson, O.
    Ahren, B.
    DIABETOLOGIA, 2019, 62 : S76 - S76
  • [45] A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
    Han, Eugene
    Park, Hye Sun
    Kwon, Obin
    Choe, Eun Yeong
    Wang, Hye Jin
    Lee, Yong-ho
    Lee, Sang-Hak
    Kim, Chul Hoon
    Kim, Lee-Kyung
    Kwak, Soo Heon
    Park, Kyong Soo
    Kim, Chul Sik
    Kang, Eun Seok
    MEDICINE, 2016, 95 (44)
  • [46] Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes
    Hashimoto K.-I.
    Horikawa Y.
    Takeda J.
    Diabetology International, 2016, 7 (2) : 133 - 140
  • [47] A Polymorphism in GLP-1 Receptor Gene Is Associated with DPP-4 Inhibitor Response in Patients with Type 2 Diabetes
    Han, Eugene
    Park, Hye Sun
    Kwon, Obin
    Kim, Gyuri
    Kim, So Ra
    Kwak, Soo-Heon
    Lee, Ji-Yeon
    Choe, Eun Yeong
    Wang, Hye Jin
    Lee, Yong-Ho
    Kim, Chul Hoon
    Lee, Sang-Hak
    Lee, Byung Wan
    Cha, Bong Soo
    Kang, Eun Seok
    DIABETES, 2016, 65 : A422 - A422
  • [48] Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naive, well-controlled type 2 diabetes subjects
    Alsalim, Wathik
    Goransson, Olga
    Carr, Richard D.
    Bizzotto, Roberto
    Tura, Andrea
    Pacini, Giovanni
    Mari, Andrea
    Ahren, Bo
    DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 1080 - 1085
  • [49] Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis
    Chen, Cai
    Yu, Qilin
    Zhang, Shu
    Yang, Ping
    Wang, Cong-Yi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 14141 - 14150
  • [50] Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
    Alsalim, Wathik
    Persson, Margaretha
    Ahren, Bo
    DIABETES OBESITY & METABOLISM, 2018, 20 (07): : 1652 - 1658
12345